Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for brain and centrally mediated diseases. Its pipeline spans neurodegenerative conditions, neuropsychiatric disorders, and metabolic diseases, with product candidates targeting novel mechanisms of action. Key programs include navacaprant, an oral kappa opioid receptor antagonist in Phase 3 clinical development for major depressive disorder, and NMRA-511, a vasopressin 1a receptor antagonist evaluated for agitation associated with Alzheimer’s disease. In addition, the company is advancing NMRA-898, an M4 receptor positive allosteric modulator for schizophrenia, and NMRA-215, an oral brain-penetrant NLRP3 inhibitor for obesity. As a clinical-stage development firm, it currently targets patient populations in clinical trials rather than commercial consumers.

The company conducts its drug discovery, clinical studies, and business operations in the United States, maintaining its principal executive offices in Watertown, Massachusetts. The provided text does not disclose physical store counts or broader international operational facilities.

Summary of the business section of Neumora Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 96 full-time employees, 56 of whom were primarily engaged in research and development activities.”